IceCure Medical (ICCM) Expected to Announce Quarterly Earnings on Tuesday

IceCure Medical (NASDAQ:ICCM) is projected to post its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect IceCure Medical to post earnings of ($0.03) per share and revenue of $1.3440 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 11:00 AM ET.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Sunday, February 15th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $1.28 million for the quarter. IceCure Medical had a negative return on equity of 221.04% and a negative net margin of 445.61%. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

IceCure Medical Price Performance

ICCM stock opened at $0.24 on Monday. The business’s 50-day moving average is $0.45 and its two-hundred day moving average is $0.59. The firm has a market capitalization of $19.48 million, a P/E ratio of -1.00 and a beta of 0.47. IceCure Medical has a 1 year low of $0.24 and a 1 year high of $1.40.

Institutional Investors Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Jane Street Group LLC purchased a new stake in IceCure Medical Ltd. (NASDAQ:ICCM) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned approximately 0.16% of IceCure Medical as of its most recent SEC filing. Institutional investors own 0.62% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ICCM. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Finally, Alliance Global Partners assumed coverage on shares of IceCure Medical in a research report on Monday, May 4th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.